CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BSIRT1OverexpressionPrognosticSupportsPoor OutcomePancreatic Ductal CarcinomaStenzinger et al., 2013
BFLT3TKD MUTATIONPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaMidostaurinFischer et al., 2010
BTP53P72RPrognosticDoes Not SupportPoor OutcomeLung CarcinomaMatakidou et al., 2003
BSMAD4ExpressionPrognosticSupportsBetter OutcomePancreatic Ductal AdenocarcinomaTascilar et al., 2001
DFANCCLoss-of-functionPredictiveSupportsSensitivity/ResponsePancreatic CancerMelphalan,Chlorambucil,Cisplatin,Mitomycin,Gemcitabinevan der Heijden et al., 2005
CEBF1::PDGFRBFusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeImatinibWeston et al., 2013
BKRASG12DPrognosticSupportsPoor OutcomeMalignant Exocrine Pancreas NeoplasmRachakonda et al., 2013
BFLT3T227MPredictiveSupportsAdverse ResponseRenal Cell CarcinomaSunitinibvan Erp et al., 2009
BPALB2L531FS*30DiagnosticSupportsPositiveBreast CancerErkko et al., 2008
DFGFR2N550KPredictiveSupportsSensitivity/ResponseEndometrial CancerPD173074Byron et al., 2008
DALKF1174LPredictiveSupportsSensitivity/ResponseNeuroblastomaAZD3463Wang et al., 2016
DALKF1245CPredictiveSupportsSensitivity/ResponseNeuroblastomaLorlatinibInfarinato et al., 2016
CALKF1245CPredictiveSupportsResistanceNeuroblastomaCrizotinibMossé et al., 2013
DALKExon 4-11 DeletionPredictiveSupportsSensitivity/ResponseNeuroblastomaBrigatinibSiaw et al., 2016
CEML4::ALKFusion AND ALK F1245CPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibKodityal et al., 2016
DEML4::ALKe6::e20PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibFriboulet et al., 2014
DALKG1269A AND v::ALK FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibFriboulet et al., 2014
DEML4::ALKFusion AND ALK T1151dupPredictiveSupportsResistanceLung Non-small Cell CarcinomaAlectinibKatayama et al., 2012
DEML4::ALKFusion AND ALK T1151dupPredictiveSupportsResistanceLung Non-small Cell CarcinomaALK Inhibitor TAE684Katayama et al., 2012
DEML4::ALKFusion AND ALK G1202RPredictiveSupportsResistanceCancerAlectinibFontana et al., 2015
DEML4::ALKFusion AND ALK G1202RPredictiveSupportsResistanceCancerBrigatinibFontana et al., 2015
DALKG1269A AND v::ALK FusionPredictiveSupportsResistanceCancerAlectinibFontana et al., 2015
CALKG1202R AND v::ALK FusionPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibKatayama et al., 2012
DPIK3CAMutationPredictiveSupportsSensitivity/ResponseHead And Neck CancerDactolisibLui et al., 2013
BRETM918TPredictiveSupportsSensitivity/ResponseMedullary Thyroid CarcinomaSorafenibLam et al., 2010
BCDK4AmplificationPredictiveSupportsSensitivity/ResponseLiposarcomaPalbociclibDickson et al., 2013
CALKI1171PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibOu et al., 2015
BNPM1EXON 11 MUTATIONPrognosticDoes Not SupportBetter OutcomeAcute Myeloid LeukemiaBoissel et al., 2005
DCDKN2ALossPredictiveSupportsSensitivity/ResponseRenal Cell CarcinomaPalbociclibLogan et al., 2013
DCDKN2BLossPredictiveSupportsSensitivity/ResponseRenal Cell CarcinomaPalbociclibLogan et al., 2013
DCDKN2ALossPredictiveSupportsSensitivity/ResponseSkin MelanomaPalbociclibYoung et al., 2014
DCDKN2ALossPredictiveSupportsSensitivity/ResponseOvarian CancerPalbociclibKonecny et al., 2011
BASXL1MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaMetzeler et al., 2011
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibUtermark et al., 2012
DERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseHer2-receptor Positive Breast CancerTgx 221Utermark et al., 2012
BPTENLossPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEsteva et al., 2010
BPTENLossPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumabEsteva et al., 2010
BCSF3RMutationDiagnosticSupportsPositiveChronic Neutrophilic LeukemiaMaxson et al., 2013
BCSF3RMutationDiagnosticSupportsPositiveAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeMaxson et al., 2013
BEGFRT790MPredictiveSupportsResistanceLung AdenocarcinomaGefitinib,ErlotinibYu et al., 2013
CEGFRS768IPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaErlotinibHellmann et al., 2014
CBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibSahadudheen et al., 2016
DPIK3CAAmplificationPredictiveSupportsSensitivity/ResponseStomach CarcinomaAlpelisibFritsch et al., 2014
BBRAFMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerPanitumumab,CetuximabPietrantonio et al., 2015
BBRAFV600EPredictiveSupportsReduced SensitivityColorectal CancerDabrafenibFalchook et al., 2012
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Cetuximab,GefitinibPrahallad et al., 2012
BBRAFV600EPredictiveSupportsSensitivity/ResponseSkin MelanomaVemurafenibSosman et al., 2012
BSMAD4LOSSPrognosticSupportsPoor OutcomePancreatic CancerIacobuzio-Donahue et al., 2009
BBRAFV600EPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerPanitumumab,VemurafenibYaeger et al., 2015
DTRIM24::BRAFFusionPredictiveSupportsResistanceSkin MelanomaVemurafenibHutchinson et al., 2013
Page 35 of 96
PreviousNext